GlassScriptPhysician profile
Fadi Chahin
NPI 1578577920
$2,428.62
in general payments reported to CMS, 2019-2025
9 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Plastic Surgery Within The Head and Neck provider received nationally (typical 2025 total: $300).
See the full distribution for Plastic Surgery Within the Head and Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $389 · 2021: $24.15 · 2022: $740 · 2023: $552 · 2024: $109 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.12 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Botox |
| Allergan, INC. | $567.02 | 2019-2022 | |
| Integra Lifesciences Corporation | $378.39 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tepha INC | $352.70 | 2019-2020 | |
| Sientra, INC. | $175.91 | 2022 | |
| Davol INC. | $140.18 | 2019-2020 | |
| Medtronic, INC. | $25.16 | 2025 | Transorb |
| Aroa Biosurgery Incorporated | $23.48 | 2024 | |
| Vioptix INC | $20.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Chahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.